Madrigal Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BIT:1MDGL Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
18 May 26	Sell€374,113	David Soergel	Individual	844	€443.26
06 Mar 26	Sell€240,582	Mardi Dier	Individual	646	€372.42
06 Mar 26	Sell€134,071	Shannon Kelley	Individual	360	€372.42
06 Mar 26	Sell€619,332	William Sibold	Individual	1,663	€372.42
06 Mar 26	Sell€182,858	Rebecca Taub	Individual	491	€372.42
06 Mar 26	Sell€156,043	Carole Huntsman	Individual	419	€372.42
02 Mar 26	Sell€432,714	Mardi Dier	Individual	1,183	€365.78
26 Jan 26	Sell€140,870	Carole Huntsman	Individual	340	€414.32
26 Jan 26	Sell€268,066	Rebecca Taub	Individual	647	€414.32
26 Jan 26	Sell€653,386	William Sibold	Individual	1,577	€414.32
20 Jan 26	Sell€936,118	Rebecca Taub	Individual	2,238	€418.28
20 Jan 26	Sell€110,009	Shannon Kelley	Individual	263	€418.28
21 Nov 25	Sell€941,765	Carole Huntsman	Individual	1,958	€490.95
09 Sep 25	Sell€2,767,884	William Sibold	Individual	7,279	€380.26
20 Aug 25	Buy€48,623,982	Baker Bros. Advisors LP	Company	151,707	€336.39
20 Aug 25	Buy€4,479,488	667, L.P.	Company	13,976	€336.39
18 Aug 25	Sell€140,776	Shannon Kelley	Individual	458	€307.37

Insider Trading Volume

Insider Buying: 1MDGL insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 1MDGL?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	850,703	3.31%
Individual Insiders	1,210,613	4.71%
Hedge Funds	7,144,374	27.8%
Institutions	16,495,122	64.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 80.55% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
8.76%	Janus Henderson Group Ltd.	2,018,647	€864.7m	27.4%	0.38%
8.65%	RTW Investments, LP	1,993,687	€854.0m	0%	9.45%
8.42%	Baker Bros. Advisors LP	1,940,318	€831.2m	-9.4%	5.39%
7.89%	Avoro Capital Advisors LLC	1,818,181	€778.9m	0.59%	10.29%
6.04%	Paulson & Co. Inc.	1,392,188	€596.4m	-18.5%	16.2%
4.63%	BlackRock, Inc.	1,067,346	€457.2m	-31.6%	0.01%
3.65%	Vanguard Portfolio Management, LLC	841,145	€360.3m	0%	0.02%
3.59%	Vanguard Capital Management, LLC	827,144	€354.3m	0%	0.01%
3.01%	Wellington Management Group LLP	694,958	€297.7m	50.6%	0.06%
2.84%	SQN, LLC	655,540	€280.8m	0%	no data
2.64%	State Street Global Advisors, Inc.	609,525	€261.1m	4.55%	0.01%
2.22%	FMR LLC	511,622	€219.2m	16.6%	0.01%
1.98%	Geode Capital Management, LLC	455,870	€195.3m	0.91%	0.01%
1.97%	Citadel Advisors LLC	453,843	€194.4m	1,160%	0.16%
1.91%	Rebecca Taub	441,033	€188.9m	0%	no data
1.6%	Frederick Craves	368,004	€157.6m	0%	no data
1.54%	William Blair Investment Management, LLC	354,222	€151.7m	-3.72%	0.24%
1.42%	T. Rowe Price Group, Inc.	328,110	€140.6m	4.61%	0.01%
1.35%	Invesco Ltd.	311,732	€133.5m	-4.71%	0.04%
1.25%	Polar Capital Holdings Plc	289,310	€123.9m	7.09%	0.38%
1.15%	Armistice Capital LLC	264,583	€113.3m	-0.42%	3.85%
1.08%	Hood River Capital Management LLC	249,511	€106.9m	0.79%	1.24%
1.05%	Lord, Abbett & Co. LLC	242,726	€104.0m	-0.85%	0.37%
0.98%	Point72 Asset Management, L.P.	225,510	€96.6m	78.4%	0.2%
0.94%	Charles Schwab Investment Management, Inc.	216,720	€92.8m	0%	0.01%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/31 08:19
End of Day Share Price	2026/07/31 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Madrigal Pharmaceuticals, Inc. is covered by 27 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Eliana Merle	Barclays
Matthew Luchini	BMO Capital Markets Equity Research
Jason Zemansky	BofA Global Research